[{"title":"The Virtual CVOT Summit 2023 will start on 30 November at 15:00 CET.","time":"","speaker":"","day":0,"start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":0,"start":"","minutes":"999999999999999"},{"title":"The livestream will start today at 15:00 CET.","time":"","speaker":"","day":0,"start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":0,"start":"","minutes":"999999999999999"},{"title":"Welcome and Introduction","time":"15:00 \u2013 15:10 CET","speaker":"Schnell O (Munich, Germany)","day":"do","start":"15:00:00","minutes":0},{"title":"Management of CKD in 2023: an update of guidelines","time":"15:10 \u2013 15:25 ","speaker":"Groop P-H (Helsinki, Finland)","day":"do","start":"15:10:00","minutes":10},{"title":"What`s new in the ESC \u201cDiabetes and the Heart\u201d and \u201cHeart Failure\u201d Guidelines 2023","time":"15:25 \u2013 15:40 ","speaker":"Marx N (Aachen, Germany)","day":"do","start":"15:25:00","minutes":25},{"title":"Discussion","time":"15:40 \u2013 15:50","speaker":"","day":"do","start":"15:40:00","minutes":40},{"title":"Treatment for Type 2 Diabetes: systematic review and network meta-analysis for the creation of living guidelines","time":"15:50 \u2013 16:05 ","speaker":"Ryd\u00e9n L (Stockholm, Sweden)","day":"do","start":"15:50:00","minutes":50},{"title":"Join the Alliance for Living Evidence (Alive)!","time":"16:05 \u2013 16:20 ","speaker":"Tendal Jeppesen B (Copenhagen, Denmark)","day":"do","start":"16:05:00","minutes":65},{"title":"Strengthening the recognition of minority groups in clinical guidelines for diabetes","time":"16:20 \u2013 16:35","speaker":"Gavin JR (Atlanta, USA)","day":"do","start":"16:20:00","minutes":80},{"title":"Discussion","time":"16:35 \u2013 16:50","speaker":"","day":"do","start":"16:35:00","minutes":95},{"title":"Break","time":"16:50 \u2013 17:00 CET","speaker":"","day":"do","start":"16:50:00","minutes":110},{"title":"Consensus statement on PROs - why, how and what does it matter?","time":"17:00 \u2013 17:15 ","speaker":"Barnard-Kelly K (Hampshire, UK)","day":"do","start":"17:00:00","minutes":120},{"title":"IDF perspective on PROs","time":"17:15 \u2013 17:30","speaker":"Schwarz P (Dresden, Germany)","day":"do","start":"17:15:00","minutes":135},{"title":"PROs: What are governments doing in this space and how do they influence policy?","time":"17:30 \u2013 17:45","speaker":"Taylor B (Tampa, USA)","day":"do","start":"17:30:00","minutes":150},{"title":"Patient\u00b4s perspectives on PROs","time":"17:45 \u2013 18:00","speaker":"Huntley G (Indianapolis, USA)","day":"do","start":"17:45:00","minutes":165},{"title":"Discussion","time":"18:00 \u2013 18:30","speaker":"","day":"do","start":"18:00:00","minutes":180},{"title":"Break","time":"18:30 \u2013 18:45 CET","speaker":"","day":"do","start":"18:30:00","minutes":210},{"title":"Multireceptor drugs for obesity: a new emerging universe","time":"18:45 \u2013 19:05","speaker":"M\u00fcller T (Munich, Germany)","day":"do","start":"18:45:00","minutes":225},{"title":"Discussion","time":"19:05 \u2013 19:15","speaker":"","day":"do","start":"19:05:00","minutes":245},{"title":"New horizons for CGM in diabetes: further building a key pillar of diabetes management","time":"19:15 \u2013 19:35","speaker":"Battelino T (Ljubljana, Slovenia)","day":"do","start":"19:15:00","minutes":255},{"title":"Discussion","time":"19:35 \u2013 19:45","speaker":"","day":"do","start":"19:35:00","minutes":275},{"title":"OP 1: Lipid-Lowering Treatments and Risk of Cardiovascular Events in Over 9000 Patients From 14 European Countries: 1-year Prospective Follow-Up of the SANTORINI Registry","time":"","speaker":"Aguiar C (Carnaxide, Portugal)","day":"do","start":"","minutes":"999999999999999"},{"title":"OP 2: Benefit of Dual Therapy With GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 Diabetes","time":"","speaker":"Kvist K (S\u00f8borg, Denmark)","day":"do","start":"","minutes":"999999999999999"},{"title":"OP 3: Tirzepatide Reduces Albuminuria in Patients With Type 2 Diabetes: Post-Hoc Pooled Analysis of SURPASS 1-5","time":"","speaker":"Ranta K (Helsinki, Finland)","day":"do","start":"","minutes":"999999999999999"},{"title":"OP 4: Impact of Finerenone on Chronic Kidney Disease Progression in Chinese Patients With Type 2 Diabetes: FIGARO-DKD Subgroup Analysis","time":"","speaker":"Brinker M (Wuppertal, Germany)","day":"do","start":"","minutes":"999999999999999"},{"title":"OP 5: A cross-sectional survey on CKD diagnosis and management","time":"","speaker":"R\u00f6tzer R (Munich, Germany)","day":"do","start":"","minutes":"999999999999999"},{"title":"Closing of Day 1","time":"20:45 CET","speaker":"","day":"do","start":"20:45:00","minutes":345},{"title":"","time":"","speaker":"","day":"do","start":"","minutes":"999999999999999"},{"title":"The Virtual CVOT Summit 2023 continues tomorrow, Friday December 01, at 08:30 CET. We look forward to your participation!","time":"","speaker":"","day":"do","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"do","start":"","minutes":"999999999999999"},{"title":"The Virtual CVOT Summit 2023 continues tomorrow, Friday, 01 December, at 08:30 CET. We look forward to your participation!","time":"","speaker":"","day":"do","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"do","start":"","minutes":"999999999999999"},{"title":"The livestream will start today at 08:30 CET.","time":"","speaker":"","day":"do","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"do","start":"","minutes":"999999999999999"},{"title":"Type 1 Diabetes: early detection and preventive approaches","time":"08:30 \u2013 08:45","speaker":"Larsson HE (Lund, Sweden)","day":"fr","start":"08:30:00","minutes":0},{"title":"Teplizumab \u2013 Delaying the onset of Type 1 Diabetes","time":"08:45 \u2013 09:00","speaker":"Mathieu C (Leuven, Belgium)","day":"fr","start":"08:45:00","minutes":15},{"title":"Treatment strategies for neuropathy in Type 1 Diabetes","time":"09:00 \u2013 09:15 ","speaker":"Tesfaye S (Sheffield, UK)","day":"fr","start":"09:00:00","minutes":30},{"title":"Preventing and delaying the progression of chronic kidney disease (CKD) in Type 1 Diabetes ","time":"09:15 \u2013 09:30 ","speaker":"Groop P-H (Helsinki, Finland)","day":"fr","start":"09:15:00","minutes":45},{"title":"Discussion","time":"09:30 \u2013 09:50","speaker":"","day":"fr","start":"09:30:00","minutes":60},{"title":"Break","time":"09:50 \u2013 10:00  CET","speaker":"","day":"fr","start":"09:50:00","minutes":80},{"title":"Self-rated knowledge and competence regarding the management of chronic kidney disease in primary care","time":"10:00 \u2013 10:15","speaker":"Topsever P (Istanbul, Turkey)","day":"fr","start":"10:00:00","minutes":90},{"title":"Shaping the role of primary care in diagnosis of CKD ","time":"10:15 \u2013 10:30","speaker":"Itzhak B (Haifa, Israel)","day":"fr","start":"10:15:00","minutes":105},{"title":"Identifying people with CKD in primary care: the role of POCT in KDIGO Guidelines","time":"10:30 \u2013 10:45","speaker":"Jacob S (Villingen-Schwenningen, Germany)","day":"fr","start":"10:30:00","minutes":120},{"title":"Diagnosing CKD with UACR in China - Paving the Way for Effective Treatment","time":"10:45 \u2013 11:00","speaker":"Yu X (Tongji, China) ","day":"fr","start":"10:45:00","minutes":135},{"title":"Discussion","time":"11:00 \u2013 11:15","speaker":"","day":"fr","start":"11:00:00","minutes":150},{"title":"Break","time":"11:15 \u2013 11:30 CET","speaker":"","day":"fr","start":"11:15:00","minutes":165},{"title":"SGLT-2 inhibitors in CKD: new outcomes to strengthen the bridge to clinical care","time":" 11:30 \u2013 11:50","speaker":"Heerspink H (Groningen, Netherlands)","day":"fr","start":" 11:3:00","minutes":153},{"title":"Non-steroidal MRAs: recent and future perspectives","time":"11:50 \u2013 12:10","speaker":"Rossing P (Copenhagen, Denmark)","day":"fr","start":"11:50:00","minutes":200},{"title":"Discussion","time":"12:10 \u2013 12:30","speaker":"","day":"fr","start":"12:10:00","minutes":220},{"title":"Current and future aspects of heart failure management","time":"12:30 \u2013 12:45","speaker":"Kosiborod M (Kansas City, USA)","day":"fr","start":"12:30:00","minutes":240},{"title":"CLEAR Outcomes: Reducing cardiovascular mortality and morbidity with bempedoic acid","time":"12:45 \u2013 13:00 ","speaker":"Ray KK (London, UK) ","day":"fr","start":"12:45:00","minutes":255},{"title":"Discussion","time":"13:00 \u2013 13:15","speaker":"","day":"fr","start":"13:00:00","minutes":270},{"title":"Break","time":"13:15 \u2013 13:45 CET","speaker":"","day":"fr","start":"13:15:00","minutes":285},{"title":"Type 2 Diabetes & Cancer ","time":"13:45 \u2013 14:00","speaker":"Standl E (Munich, Germany)","day":"fr","start":"13:45:00","minutes":315},{"title":"Obesity & Cancer","time":"14:00 \u2013 14:15 ","speaker":"Herzig S (Munich, Germany)","day":"fr","start":"14:00:00","minutes":330},{"title":"Discussion","time":"14:15 \u2013 14:30","speaker":"","day":"fr","start":"14:15:00","minutes":345},{"title":"Recent advances in incretin therapy","time":"14:30 \u2013 14:50","speaker":"Fr\u00edas JP (Los Angeles, USA)","day":"fr","start":"14:30:00","minutes":360},{"title":"Successful treatment of Type 2 Diabetes and obesity: managing cardiovascular risk and implementing new treatment pathways","time":"14:50 \u2013 15:10 ","speaker":"Vilsb\u00f8ll T (Copenhagen, Denmark)","day":"fr","start":"14:50:00","minutes":380},{"title":"Diagnosis, prognosis and future treatments options of fatty liver disease ","time":"15:10 \u2013 15:30 ","speaker":"Tacke F (Berlin, Germany)","day":"fr","start":"15:10:00","minutes":400},{"title":"How to communicate successfully with people who are obese","time":"15:30 \u2013 15:50","speaker":"Snoek F (Amsterdam, Netherlands)","day":"fr","start":"15:30:00","minutes":420},{"title":"Discussion","time":"15:50 \u2013 16:15","speaker":"","day":"fr","start":"15:50:00","minutes":440},{"title":"Break","time":"16:15 \u2013 16:30 CET","speaker":"","day":"fr","start":"16:15:00","minutes":465},{"title":"Industry\u00b4s perspective - panel discussion ","time":"16:30 \u2013 17:30 CET","speaker":"","day":"fr","start":"16:30:00","minutes":480},{"title":"OP 6: Change in Fibrosis-4 Index (FIB4) is Associated With Risk of Liver Events, Cardiovascular Events, and All-Cause Mortality in Patients With Obesity and\/or Type 2 Diabetes (T2D)","time":"","speaker":"Jara M (S\u00f8borg, Denmark)","day":"fr","start":"","minutes":"999999999999999"},{"title":"OP 7: Prevalence and Effect of Semaglutide on Non-Alcoholic Steatohepatitis in People With Obesity With and Without Type 2 Diabetes: Analyses From the STEP 1 and 2 Trials Using SomaSignal Tests","time":"","speaker":"Long M (S\u00f8borg, Denmark)","day":"fr","start":"","minutes":"999999999999999"},{"title":"OP 8: Heart Failure in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease With and Without Cardiovascular Autonomic Neuropathy","time":"","speaker":"Monashnenko O (Kyiv, Ukraine)","day":"fr","start":"","minutes":"999999999999999"},{"title":"OP 9: Glycaemic Control in Users of Automated Insulin Delivery Systems Increased Slightly From 2019 to 2021: Longitudinal Data of the Digitalisation and Technology Report","time":"","speaker":"Ehrmann D (Bad Mergentheim, Germany)","day":"fr","start":"","minutes":"999999999999999"},{"title":"OP 10: Real-World Evidence Showing Sustained Improvements in Glycemia at 1 Year in People With Type 2 Diabetes Using the OneTouch Reveal\u00ae Mobile App With OneTouch\u00ae Blood Glucose Meters","time":"","speaker":"Holt E (Malvern, USA)","day":"fr","start":"","minutes":"999999999999999"},{"title":"Abstract Awards and Closing","time":"18:30 \u2013 18:45 CET ","speaker":"Schnell O (Munich, Germany) ","day":"fr","start":"18:30:00","minutes":600},{"title":"","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"Thank you for your attendance and contribution to the Virtual CVOT Summit 2023. <br\/>See you next year for and contribution to the Virtual CVOT Summit 2023. <br\/>See you next year for the 10th CVOT Summit on 05 - 06 December , 2024.","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"Thank you for your attendance and contribution to the Virtual CVOT Summit 2023. <br\/>See you next year for and contribution to the Virtual CVOT Summit 2023. <br\/>See you next year for the 10th CVOT Summit on 05 - 06 December , 2024. ","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"We will be right back.","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"We are currently having some technical issues. We will be right back.","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"The page is automatically updated.","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"},{"title":"The next program item is loaded.","time":"","speaker":"","day":"fr","start":"","minutes":"999999999999999"}]